Clinical Trial Detail

NCT ID NCT01682213
Title Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

melanoma

Therapies

Dabrafenib

Age Groups: adult

Additional content available in CKB BOOST